Erasca, Inc.
ERAS
Pozycja w akcjach
#3613
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Cena akcji
$13.45
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$4.70B
Zmiana (1 dzień)
-9.58%
Zmiana (1 rok)
455.58%
Kraj
US
Handel Erasca, Inc. (ERAS)
Kategoria
Healthcare
EPS dla Erasca, Inc. (ERAS)
EPS na dzień June 2026 TTM: $-0.95
Według najnowszych raportów finansowych i ceny akcji firmy Erasca, Inc., obecny EPS (TTM) wynosi $-0.95. Na koniec roku 2023 firma miała EPS w wysokości $-0.83, spadek w porównaniu do do EPS z roku 2022, który wynosił $-1.99.
Historia EPS dla Erasca, Inc. od 2019 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
